Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

被引:2
|
作者
Gualano, Bruno [1 ,2 ]
Saad, Carla G. S. [3 ]
Sieczkowska, Sofia M. [1 ]
Lemes, Italo Ribeiro [1 ]
da Silva, Rafael Pires [1 ]
Pinto, Ana J. [1 ,4 ]
Mazzolani, Bruna C. [1 ]
Smaira, Fabiana, I [1 ]
Gil, Saulo [1 ]
Oliveira-Junior, Gersiel [1 ]
Aikawa, Nadia E. [3 ]
Medeiros-Ribeiro, Ana C. [3 ]
Silva, Clovis A. [3 ,5 ]
Yuki, Emily F. N. [3 ]
Pasoto, Sandra G. [3 ]
Pereira, Rosa Maria R. [3 ]
Shinjo, Samuel K. [3 ]
Andrade, Danieli C. O. [3 ]
Sampaio-Barros, Percival D. [3 ]
Roschel, Hamilton [1 ]
Bonfa, Eloisa [3 ]
机构
[1] Univ Sao Paulo, Fac Med FMUSP, Sch Phys Educ & Sport, Div Rheumatol,Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Rheumatol, Sao Paulo, Brazil
[4] Univ Colorado, Sch Med, Metab & Diabet & Anschutz Hlth & Wellness Ctr, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA
[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente,Pediat Rheumatol Unit, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; immunosuppression; physical activity; resistance exercise; Sinovac-CoronaVac; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; RESPONSES; EFFICACY; ANTIBODY; ADJUVANT;
D O I
10.1152/japplphysiol.00015.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. NEW & NOTEWORTHY We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [31] Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
    Medeiros-Ribeiro, Ana Cristina
    Bonfiglioli, Karina Rossi
    Domiciano, Diogo Souza
    Shimabuco, Andrea Yukie
    da Silva, Henrique Carrico
    Saad, Carla G. S.
    Yuki, Emily Figueiredo Neves
    Pasoto, Sandra Gofinet
    Renner Araujo, Carlo Scognamiglio
    Nakai, Tatiane Lie
    Silva, Clovis Artur
    Pedrosa, Tatiana
    Kanda Kupa, Leonard de Vinci
    Rodrigues Silva, Matheus Santos
    Moreira Balbi, Guilherme Guimaraes
    Kallas, Esper Georges
    Aikawa, Nadia Emi
    Bonfa, Eloisa
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 710 - 719
  • [32] Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
    Wu, Yufei
    Huang, Ping
    Xu, Mingjie
    Zhao, Qianqian
    Xu, Yihui
    Han, Shuyi
    Li, Huanjie
    Wang, Yunshan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] VITT with inactivated SARS-CoV-2 vaccine - index case
    Devi, Kanta
    Ali, Natasha
    Nasir, Nosheen
    Mahmood, Syed Faisal
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [34] Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
    Strengert, Monika
    Becker, Matthias
    Ramos, Gema Morillas
    Dulovic, Alex
    Gruber, Jens
    Juengling, Jennifer
    Luerken, Karsten
    Beigel, Andrea
    Wrenger, Eike
    Lonnemann, Gerhard
    Cossmann, Anne
    Stankov, Metodi, V
    Dopfer-Jablonka, Alexandra
    Kaiser, Philipp D.
    Traenkle, Bjoern
    Rothbauer, Ulrich
    Krause, Gerard
    Schneiderhan-Marra, Nicole
    Behrens, Georg M. N.
    EBIOMEDICINE, 2021, 70
  • [35] Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
    Bai, Shuang
    Zhou, Shanshan
    Zhang, Junnan
    Chen, Weixin
    Lv, Min
    Wang, Jian
    Zhang, Ao
    Wu, Jiang
    Zhao, Wei
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents
    Kamei, Koichi
    Ogura, Masao
    Sato, Mai
    Nishi, Kentaro
    Shoji, Kensuke
    Funaki, Takanori
    Ogimi, Chikara
    Ito, Shuichi
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [37] Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
    Han, Yuling
    Yang, Jiaxin
    He, Danshuang
    Feng, Yang
    Liu, Xiaoman
    Min, Yu
    Fan, Shenghao
    Yin, Guobing
    Hu, Daixing
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
    Murt, Ahmet
    Altiparmak, Mehmet Riza
    Yadigar, Serap
    Yalin, Serkan Feyyaz
    Ozbey, Dogukan
    Yildiz, Zeynep
    Kocazeybek, Bekir
    Pekpak, Meltem
    Ataman, Muveddet Rezzan
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (04) : 769 - 774
  • [39] Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study
    Cai, Shaohang
    Liao, Guichan
    Yu, Tao
    Gao, Qiqing
    Zou, Lirong
    Zhang, Huan
    Xu, Xuwen
    Chen, Juanjuan
    Lu, Aili
    Wu, Yingsong
    Li, Baisheng
    Peng, Jie
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4224 - 4233
  • [40] Viral dynamics of SARS-CoV-2 in immunocompromised patients
    Utzon, Andrea N.
    Johansen, Isik S.
    Bang, Line L.
    Pedersen, Rune M.
    Andersen, Thomas E.
    Madsen, Lone W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (08) : 1087.e1 - 1087.e3